Syncom Formulations Launches "Saksham Niveshak" Campaign for Unclaimed Dividends
This initiative is a compliance and shareholder service activity, responding to a regulatory request. It does not directly impact the company's core business operations, financial performance, or strategic direction significantly, but is important for good governance and shareholder relations.
The campaign directly benefits shareholders by assisting them in claiming their unpaid/unclaimed dividends, preventing their transfer to the IEPF, thus improving shareholder relations.
* Syncom Formulations (India) Limited has launched a 100-day campaign called "Saksham Niveshak" from 28th July 2025 to 6th November 2025. * This initiative is in response to a request from the Investor's Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs (MCA), dated July 16, 2025. * The campaign's primary purpose is to create awareness among shareholders to update their KYC details and claim any unpaid or unclaimed dividends before they are transferred to the IEPF. * The Company stated it had already been proactively sending annual reminder letters to shareholders to update their details and claim entitlements. * Shareholders are urged to update essential information such as PAN, Nomination details, Contact information (postal address, mobile number), Bank account details, and Specimen signature with the Company or its Registrar & Transfer Agent, Ankit Consultancy Private Limited. * Dividends are payable only through electronic mode, making updated bank details crucial for payment. * Required forms like ISR-1, ISR-2, SH-13, and ISR-3 can be downloaded from the Company's or RTA's website. * Documents can be submitted by post to Ankit Consultancy Pvt Ltd. or Syncom Formulations (India) Ltd. * Shareholders holding shares in electronic form who have not claimed their dividend should update/modify their details with their respective Depository Participants (DPs). * The deadline for submitting documents to support this campaign is 6th November 2025.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.